# Junta clínica — PT-pseudo_e91d5fe837cb (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_e91d5fe837cb",
  "pid": "PT-pseudo_e91d5fe837cb",
  "task": 1,
  "psa": 6.1,
  "age": 63,
  "months": 1,
  "pirads": "4",
  "psad": 0.12,
  "psav": 0.89,
  "psap": 5.3,
  "vol": 50.0,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.6372923,
  "medhx": "Hypercholesterolaemia, Chronic kidney disease, Benign prostatic hyperplasia",
  "meds": "atorvastatin, simvastatin, rosuvastatin, tamsulosin",
  "notes": "PSA 6.1 ng/mL. PI-RADS 4. PSAD 0.12. Prostate volume 50 mL. DRE nodus. csPCa 0.64.",
  "pmhx": [
    "Hypercholesterolaemia",
    "Chronic kidney disease",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "77 kg",
    "height": "180 cm",
    "bmi": "23.8",
    "bp": "105/87 mmHg",
    "hr": "75 bpm",
    "smoking": "Ex-smoker (40 pack-yr, quit 2009)",
    "last_dental": "6 mo ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "18 Jan 2025",
  "enc_ref": "Dr. R. van den Berg (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Ongoing monitoring required due to previously confirmed malignancy and steadily climbing PSA levels."
    },
    {
      "s": "History",
      "t": "At age 63, this retired warehouse worker first entered clinical scrutiny for prostate irregularities toward the end of 2022. Medical background includes hypercholesterolaemia and chronic kidney disease, currently treated with atorvastatin, simvastatin, rosuvastatin, and tamsulosin. A 40 pack-year smoking history is noted, though cessation occurred back in 2009. Lower urinary tract complaints remain minimal, reflected by an IPSS score of 1/35, and he explicitly denies pelvic discomfort or blood in the urine. Marital status is divorced, and he resides independently, relying on his grown son as his main point of contact. Daily habits include roughly 20 units of alcohol per week, while physical activity consists mainly of routine gardening instead of formal workouts. Commuting to the facility takes over an hour by rail. Recent outpatient visits covered routine thyroid evaluations, a surveillance colonoscopy under gastroenterology, and a vascular surgery assessment for varicose veins. He reports no unexplained weight reduction, skeletal pain, or systemic complaints, with his primary focus remaining strictly on prostate surveillance."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: moderately enlarged gland; right posterior peripheral zone contains a firm, discrete nodule; remainder presents as symmetrically smooth. General survey shows a well-nourished gentleman without signs of acute distress. Chest auscultation reveals clear breath sounds, and cardiovascular rhythm remains regular. Abdominal palpation yields a soft, non-tender cavity devoid of palpable masses or organ enlargement."
    }
  ],
  "occupation": "retired warehouse worker",
  "marital": "Divorced",
  "living": "Lives alone",
  "next_of_kin": "Adult son (primary contact)",
  "recent_other": [
    "Endocrine — thyroid screening",
    "Gastroenterology — surveillance colonoscopy",
    "Vascular surgery — varicose veins consult"
  ],
  "alcohol": "20 units / week",
  "exercise": "Gardening, no structured exercise",
  "ipss": "IPSS score: 1/35 (mild LUTS)",
  "admin": "Patient travels 60+ min by train to clinic; allow buffer.",
  "mri_hospital": "Maastricht UMC+",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_e91d5fe837cb
Task: 1

Encounter: Urology - outpatient on 18 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 63-year-old male
  - PSA: 6.1 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.12 ng/mL²
  - PSA velocity: 0.89 ng/mL/yr
  - Prior PSA: 5.3 ng/mL
  - Prostate volume: 50.0 mL
  - Months since last PSA: 1
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.6372923 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypercholesterolaemia, Chronic kidney disease, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypercholesterolaemia, Chronic kidney disease, Benign prostatic hyperplasia
  - Current medication: atorvastatin, simvastatin, rosuvastatin, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 6.1 ng/mL. PI-RADS 4. PSAD 0.12. Prostate volume 50 mL. DRE nodus. csPCa 0.64.

Vitals: weight 77 kg, height 180 cm, BMI 23.8, BP 105/87 mmHg, HR 75 bpm. Smoking: Ex-smoker (40 pack-yr, quit 2009).

Chief complaint: Ongoing monitoring required due to previously confirmed malignancy and steadily climbing PSA levels.

History: At age 63, this retired warehouse worker first entered clinical scrutiny for prostate irregularities toward the end of 2022. Medical background includes hypercholesterolaemia and chronic kidney disease, currently treated with atorvastatin, simvastatin, rosuvastatin, and tamsulosin. A 40 pack-year smoking history is noted, though cessation occurred back in 2009. Lower urinary tract complaints remain minimal, reflected by an IPSS score of 1/35, and he explicitly denies pelvic discomfort or blood in the urine. Marital status is divorced, and he resides independently, relying on his grown son as his main point of contact. Daily habits include roughly 20 units of alcohol per week, while physical activity consists mainly of routine gardening instead of formal workouts. Commuting to the facility takes over an hour by rail. Recent outpatient visits covered routine thyroid evaluations, a surveillance colonoscopy under gastroenterology, and a vascular surgery assessment for varicose veins. He reports no unexplained weight reduction, skeletal pain, or systemic complaints, with his primary focus remaining strictly on prostate surveillance.

Physical examination: DRE — texture: moderately enlarged gland; right posterior peripheral zone contains a firm, discrete nodule; remainder presents as symmetrically smooth. General survey shows a well-nourished gentleman without signs of acute distress. Chest auscultation reveals clear breath sounds, and cardiovascular rhythm remains regular. Abdominal palpation yields a soft, non-tender cavity devoid of palpable masses or organ enlargement.

Patient info: retired warehouse worker; Divorced; Lives alone.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 20 units / week; exercise Gardening, no structured exercise; IPSS score: 1/35 (mild LUTS).

Recent other appointments: Endocrine — thyroid screening; Gastroenterology — surveillance colonoscopy; Vascular surgery — varicose veins consult.
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.64
  uncertainty  +/- 0.07 epistemic (95% band 0.50-0.78); among patients I cannot tell apart the outcome was 0.94 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = 3 on the problem list (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 63 (2% of my signal; from age) · DRE = Nodus (10% of my signal; from dre_suspicious) · PSA = 6.1 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 50 mL (1% of my signal; from log_vol, vol) · PSA density = 0.12 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.64 (1% of my signal; from cspca) · PI-RADS = 4 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: borderline — 'supports' tier; out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  important  prior biopsy = Positive
  noted      age = 63 · DRE = Nodus · PSA = 6.1 ng/mL · prostate volume = 50 mL · PSA density = 0.12 · PI-RADS = 4 · comorbidity = 3 on the problem list
  not used   family history, csPCa probability
CONFIDENCE: uncertain — none of my three panel rules applies; the fact that would settle it — the documented prior grade — lives in the notes, not on the panel

## Intervención 5 — EXPERT-EXPERIENCE

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

I recall 49 men I have seen in this same situation (Positive prior biopsy). The 3 most similar patients, and what the reading urologist did:
  1. distance 1.21: PI-RADS 4, PSA 13.2, PSAD 0.14, age 66, DRE Nodus -> BIOPSY (uncertain). He wrote: "There is no information on ISUP in the earlier cancer diagnosis and missing also size of earlier PIRADS 4 lesion"
  2. distance 1.23: PI-RADS 4, PSA 5.3, PSAD 0.1, age 56, DRE Nodus -> BIOPSY (clear). He wrote: "PIRADS 4 in a young man with a rapid increasing PSA"
  3. distance 1.33: PI-RADS 4, PSA 3.8, PSAD 0.126, age 70, DRE Nodus -> DEFER (borderline). He wrote: "stable MRi findings in 70yr with reasonably low PSA. prev biopsy finding without obvious indication for treatment. IF patient want to be very active in treatment, consid…"

PRECEDENT: BIOPSY (weighted vote 0.68 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What my professional experience contributes: it shows what this urologist looks at and how he phrases the call. These memories do not establish facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  important  prior biopsy = Positive · age = 63 · PSA = 6.1 ng/mL · PI-RADS = 4
  noted      family history = not opened (0 of 91) · DRE = Nodus · prostate volume = 50 mL · PSA density = 0.12 · comorbidity = 3 on the problem list
  not used   csPCa probability
CONFIDENCE: uncertain — in this situation the library is no better than chance (47% out of fold)

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  important  prior biopsy = Positive · age = 63 · DRE = Nodus · PSA = 6.1 ng/mL · PI-RADS = 4
  noted      family history = not opened (0 of 91) · prostate volume = 50 mL · PSA density = 0.12 · comorbidity = 3 on the problem list
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The retrieved guidelines discuss using PI-RADS thresholds to guide biopsy decisions, noting that a threshold of PI-RADS $\\ge 3$ is used to trigger biopsy, and that increasing the threshold to $\\ge 4$ could avoid a significant number of biopsies while missing some cancer.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, your bid of BIOPSY p(biopsy) = 0.64 is high, but the guideline suggests that the PI-RADS score of 4 is a factor that should be weighed against other variables. The guideline suggests that increasing the PI-RADS threshold to $\\ge 4$ could avoid 59% of biopsies, which is a context the guideline treats as a decision point, not just a variable. The guideline requires the prior grade of the prior biopsy to settle the decision, which is a fact the panel does not represent.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA velocity: the guideline suggests that PSA velocity is a factor in risk-adapted decisions, which the panel only shows as a value.
laboratory_results - the PSA density: the guideline links PSA density to the risk-adapted matrix table, which the panel only shows as a value.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

The case hinges entirely on the documented grade of the prior biopsy, which is missing from the panel and must be established in the previous notes.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine whether the lesion is compared against an earlier study.
  psa_trend (get_psa_trend) -> Determine the significance of the PSA velocity for risk-adapted decisions.
  previous_notes (get_previous_notes) -> Establish the grade (Gleason or ISUP) of the prior biopsy and surveillance status.
  laboratory_results (get_lab_results) -> Determine the risk-adapted matrix value based on the PSA density.

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the grade (Gleason or ISUP) of the prior biopsy?
  Q2. Does the radiology report indicate if the lesion is compared against an earlier study?
  Q3. What is the PSA velocity, and how does it factor into the risk-adapted decision?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: size and zone of the index lesion, as the report words it: "discrete hypointense focus in the right posterior peripheral zone at mid-gland height, spanning roughly 14 x 10 x 12 mm."

psa_trend
The significance of the PSA velocity for risk-adapted decisions: PSA trend shows a rise from 2.9 (Oct 2022) to 6.1 (Jan 2025), indicating a significant upward trajectory.

previous_notes
PRIOR GRADE: not recorded
BIOPSY SESSIONS: not recorded
SURVEILLANCE: "Immediate intervention was deemed unnecessary at that juncture."
TREATMENT: none recorded

laboratory_results
The risk-adapted matrix value based on the PSA density: PSA density is 0.12 ng/mL/mL, which is noted in the report.

WHAT I DID NOT OPEN
family-history anamnesis, as it was not requested by the plan and is not required to establish the prior biopsy grade or surveillance status.

WHAT THIS SUPPORTS
FOR sampling this patient now
PSA trend shows a significant upward trajectory, suggesting clinical concern.
PI-RADS 4 finding in the mpMRI report suggests a high-risk lesion.

AGAINST sampling this patient now
Prior biopsy grade is not recorded in the previous notes, leaving the indication for further action unclear.

WHERE THIS LEANS
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 6.10 ng/mL over 4 points spanning 27 months; velocity +1.43 ng/mL per year; doubling time about 25 months.
PROJECTION at 6 months: 7.7 ng/mL, conformal 95% band 2.2-26.9.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 6.1 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: borderline — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.57
  uncertainty  +/- 0.09 epistemic (95% band 0.40-0.74), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 4 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      DRE = Nodus (5% of my signal; from dre_suspicious) · PSA = 6.1 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 50 mL (4% of my signal; from log_vol, vol) · PSA density = 0.12 (0% of my signal; from psad_calc) · comorbidity = 3 on the problem list (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, csPCa probability
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.64  ('supports' tier; weight 2.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.57  ('discuss' tier, fusion_full; weight 1.5)
  EXPERT-EXPERIENCE  BIOPSY, p(biopsy)=0.68  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.61 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-STRUCTURED carried the most weight ('supports' tier). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           Positive                     E1:DEC E3:DEC cohort:IMP library:IMP E2:—            -> important
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:not E2:—                  -> not_used (raised from noted by the board)
  age          63                           E1:not E3:— cohort:not library:IMP E2:—              -> important
  dre          Nodus                        E1:not E3:not cohort:not library:not E2:—            -> important
  psa          6.1 ng/mL                    E1:not E3:not cohort:not library:IMP E2:not          -> important
  vol          50 mL                        E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         0.12                         E1:not E3:not cohort:not library:not E2:—            -> noted
  cspca        0.64                         E1:not E3:— cohort:— library:— E2:—                  -> not_used
  pirads       4                            E1:not E3:IMP cohort:not library:IMP E2:—            -> important
  comorbidity  3 on the problem list        E1:IMP E3:not cohort:not library:not E2:—            -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: clear.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened (radiology_report, psa_trend, previous_notes, laboratory_results) address the moderator's questions to some extent. The `previous_notes` explicitly state that the prior biopsy grade is "not recorded," directly answering Q1 by stating the information is missing from the retrieved documents.

ALIGNMENT WITH THE PANEL
The PANEL-PROTOCOL concludes BIOPSY based on a weighted vote (p=0.61) because the "documented prior grade in the opened documents: none recorded." This aligns with the finding from the `previous_notes` that the prior grade is not recorded, which is the key factor the panel used to decide.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the grade (Gleason or ISUP) of the prior biopsy? Answered by the `previous_notes`: "PRIOR GRADE: not recorded."
Q2. Does the radiology report indicate if the lesion is compared against an earlier study? Answered by the `radiology_report`: "COMPARISON: new."
Q3. What is the PSA velocity, and how does it factor into the risk-adapted decision? Answered by the `psa_trend`: "PSA trend shows a rise from 2.9 (Oct 2022) to 6.1 (Jan 2025), indicating a significant upward trajectory."

WHAT CARRIES WEIGHT, AND WHY
<prior biopsy>: not_used / noted with the value "not recorded" because the panel's decision rested on this missing piece of information, and the retrieved notes confirmed it was not recorded. I would move this to 'decisive' if the guideline strongly mandated a default action when this is missing.
<psa velocity>: important / noted with the value "rise from 2.9 (Oct 2022) to 6.1 (Jan 2025)" because the trend indicates clinical concern, which supports the expert consensus leaning towards biopsy.
My confidence in the record as it stands is borderline because the critical piece of information (prior biopsy grade) remains unestablished, despite the panel's decision.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy, leaning on the panel's decision and the significant upward PSA velocity, while explicitly noting the missing prior biopsy grade as a critical gap that must be addressed during the procedure.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

63y/o, PSA 6.1 (density 0.12), PI-RADS 4, prior biopsy positive but grade not recorded. Rising PSA trend and unrecorded prior grade mandate sampling to determine management. The lack of prior grade is the key factor driving this decision.

What carried weight: bx=important, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
